Close Menu

Breaking News

The investment firm said that Grail's revenue trajectory is uncertain, and given the firm's operating loss, it will significantly dilute Illumina's earnings.

The test is designed to detect two regions within the virus' nucleocapsid gene in upper respiratory specimens, according to the Puerto Rico-based company.

Promega will develop its microsatellite instability assay as a companion diagnostic for Incyte's anti-PD-1 drug candidate retifanlimab in endometrial cancer.

Under the non-exclusive deal, Oxford Nanopore can include the technology, which targets long DNA fragments, in its nanopore sequencing products.

The nonexclusive deal includes Personal Genome Diagnostics' US Food and Drug Administration-cleared Elio Tissue Complete cancer genomic profiling assay.

Along with the downgrade, the investment bank also lowered its December 2021 price target for Illumina from $390 to $280.

The Wilmington, Delaware-based startup will use the funds for clinical validation trials on its Arna Breast cancer diagnostic test in the US and Europe. 

After a two-year evaluation in advanced non-small cell lung cancers with Allegheny Health Network, the payor will cover the test for its regional members.

Data privacy firm Oasis Labs will offer a consumer-controlled data management app to customers of the DNA testing company, which was cofounded by George Church.

Last week, GenomeWeb's readers were most interested in rumors that sequencing giant Illumina was planning to acquire liquid biopsy firm Grail.

The deal, which was approved by the boards of directors of both companies, is expected to close in the second half of 2021, pending customary conditions.

The deal includes UK-based Yourgene's test for detecting cancer patients who may have an adverse reaction to 5-fluorouracil, as well as reproductive health tests.

One of the revisions specifies that the ID Now test is for use with specimens collected within the first week of symptom onset.

Prenetics, which operates in 10 countries, will use the funding for R&D and plans to launch a rapid coronavirus nucleic acid test in Q4.

Researchers profiled T cells in the cerebrospinal fluid of healthy individuals and multiple sclerosis patients using single-cell RNA-seq and T cell receptor sequencing.

News items for the week of Sept. 14, 2020.

The tests will be developed to identify NSCLC patients with ALK fusions and EGFR Exon20 insertion mutations who respond to mobocertinib or brigatinib.

Visby's test is a fully integrated PCR device that detects SARS-CoV-2 RNA, while SNIBE's test comprises assays for two different antibodies against the virus.

The University of Michigan spinout will use the funds to develop its InheRET platform, increase integration with EHRs, as well as increase its workforce and userbase. 

The company said it will use the capital to accelerate the growth and development of its infrastructure and CRISPR-based chips.

In 2018 Qiagen purchased a 19.9 percent stake in Ann Arbor, Michigan-based NeuMoDx along with the right to acquire the remaining shares.

The Manhattan-based lab will scale its capacity to process 20,000 tests per day by November and provide results dedicated to the city.

Participants were especially reluctant to donate their de-identified DNA and medical data to for-profit companies or to multiple entities.

Pages

The UK and the European Union have come to a sticking point in the negotiation of how the UK might remain involved in the Horizon Europe research program, the Guardian reports.

The New York Times reports that experts pushed during a meeting of an FDA advisory board for the agency to require more safety data from SARS-CoV-2 vaccine trials.

The Washington Post reports Moderna expects that it will have enough data on its candidate SARS-CoV-2 vaccine to submit to regulatory authorities by mid-November.

In Science this week: ANXA11 variants affect calcium homeostasis and stress granule disassembly in ALS, and more.